ICER releases draft evidence report on therapies for myasthenia gravis


22 July 2021 - Public comment period now open until 18 August 2021; requests to make oral comment during public meeting also being accepted.

The ICER today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of eculizumab (Soliris, Alexion Pharmaceuticals) and efgartigimod (argenx, Halozyme Therapeutics, and Zai Lab) for the treatment of myasthenia gravis.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder